EL7.AI
StocksHigh ImpactUpdated•Originally published 30 March 2026•Updated 31 March 2026•
1 min read

Corcept Therapeutics Surges on Early FDA Approval for Ovarian Cancer Drug Lifyorli

Key Facts

1Corcept Therapeutics received early FDA approval for Lifyorli (relacorilant) in platinum-resistant ovarian cancer.
2Lifyorli demonstrated a 35% reduction in the risk of death and strong tolerability in patients.
3The company issued 2026 sales guidance of $900M–$1B, driven by the growth of the new drug.

Corcept Therapeutics (CORT) has received early approval from the U.S. Food and Drug Administration (FDA) for its oncology drug Lifyorli, targeting platinum-resistant ovarian cancer. Clinical data revealed that the drug demonstrated a significant 35% reduction in the risk of death while maintaining strong tolerability among patients. Following this milestone, the company issued optimistic sales guidance for 2026, projecting revenues between $900 million and $1 billion. Analysts have subsequently upgraded the stock's rating, noting that Lifyorli is well-positioned to offset the declining sales of the company's older product, Korlym. This development marks a major shift in Corcept's long-term revenue outlook and overall market valuation. The approval underscores the growing strength of the company's biotech pipeline and its potential for sustained growth in the oncology sector.